Navigation Links
Chemo for Mesothelioma Offers Limited Survival Benefits
Date:5/15/2008

Therapy does not appear to help quality of life for lung cancer linked to asbestos,,

THURSDAY, May 15 (HealthDay News) -- Adding chemotherapy to other treatments being giving to patients with mesothelioma, a lung cancer usually linked to asbestos exposure, does not appear to improve either survival or quality of life.

Malignant pleural mesothelioma (MPM), which is usually fatal, is a cancer of the protective lining that covers the lungs. Asbestos is still produced or used in large quantities in countries such as Russia, China, Canada, Kazakhstan, Brazil, Zimbabwe, India and Thailand.

In the study, published in this week's issue of The Lancet, groups of mesothelioma patients received one of two chemotherapy regimes (four cycles of mitomycin, vinblastine and cisplatin every three weeks or one injection of vinorelbine every week for 12 weeks) in addition to active symptom control (ACS) treatments. ACS can include steroids, painkillers, bronchodilators and palliative radiotherapy to control the cancer's symptoms. Another group only received the symptom control treatments.

At the time of the analysis, roughly 96 percent of patients in all three groups had died. Only a slight but statistically insignificant improvement in survival rates after one year was found when comparing the two chemotherapy groups combined to those receiving only treatment for symptoms (32 percent vs. 29 percent).

Patients in the chemotherapy group that received vinorelbine, though, did have a slightly better survival rate (37 percent) than the other two groups but, again, researchers said this was not statistically significant.

Quality-of-life scores (physical functioning, pain, shortness of breath, overall health status) were similar in the three groups.

"The addition of chemotherapy to ASC offers no significant benefits in terms of overall survival or quality of life. However, exploratory analyses suggested that vinorelbine merits further investigation," the authors concluded.

More information

The National Cancer Institute has more about mesothelioma.



-- Kevin McKeever



SOURCE: The Lancet, news release, May 15, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Targeted therapy plus chemotherapy may pack 1-2 punch against melanoma
2. Blacks not receiving chemotherapy for rectal cancer, despite seeing cancer specialists
3. Black Rectal Cancer Patients Less Likely to Get Chemo, Radiation
4. Chemotherapy causes delayed severe neural damage
5. Common Chemotherapy Drug Linked to Memory Problems
6. Drug compound leads to death of ovarian cancer cells resistant to chemotherapy
7. Karmanos Researchers Report Enhanced Chemosensitivity of Pancreatic Cancer Cells by Black Seed Component
8. High-Dose Chemo Fails Against Small Cell Lung Cancers
9. High-intensity chemotherapy does not improve survival in small cell lung cancer
10. Most Cancer Survivors Say Chemo Fears Unfounded
11. Fasting Before Chemo Protects Healthy Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst ... third time to shed lights on the variety of topics detailing why we appreciate ... Appreciation” tackles why this career has gone from being in a major recession to ...
(Date:5/27/2016)... ... May 27, 2016 , ... An educational campaign ... inspiring human-interest stories, courtesy of awareness-driven celebrities and thought leaders. It also provides ... associations and industry leaders such as Bioness. , As patients feel increasingly ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... this installment is bolstered by inspiring human interest stories, courtesy of leaders in ... trends and tech within the industry, from leading advocates and associations—namely Jones & ...
(Date:5/27/2016)... ... May 27, 2016 , ... With a team of ... food industries. Aside from its GMP accreditation, Validation Center is also a registered ... products, services and staff. , Validation Center is ISO17025 accredited and only offers ...
(Date:5/26/2016)... Gilsum, New Hampshire (PRWEB) , ... May 26, 2016 , ... ... natural skin care products, has been honored with a 2016 When Work Works Award ... This prestigious award, part of the national When Work Works project administered by the ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... CAESAREA, Israel , May 27, 2016 ... developer of the Dario™ Diabetes Management Tool, today announced that ... present at the Marcum MicroCap Conference being held June 1-2 ... LD Micro Invitational, being held June 7-9 in ... Mr. Ben-David will discuss recent corporate and operational milestones, including ...
(Date:5/27/2016)... 2016 Kitov Pharmaceuticals ... on late-stage drug development, today announced the completion ... pivotal batches required for registration of KIT-302 with ... follows Kitov,s announcement in December 2015, ... its primary efficacy endpoint. "We are ...
(Date:5/26/2016)... -- According to a new market report published ... Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - ... valued at US$ 5.89 Bn in 2014 and is anticipated ... 2023 to reach US$ 7.99 Bn in 2023. ... free drug delivery devices and the market is estimated based ...
Breaking Medicine Technology: